Events calendar

Wegovy Indications for MASH Belkis Llerena, Pharm D ,  Novo Nordisk

Wegovy Indications for MASH

Belkis Llerena, Pharm.D., R.Ph,  Novo Nordisk

On August 15, Wegovy received a new treatment indication from the FDA for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults.

MetroCare will host Belkis Llerena, Pharm.D., R.Ph, of Novo Nordisk to discuss the new indications, screening for fibrosis, and specific steps required for authorization for coverage by commercial payers and Medicare beginning Jan 1 2026.

This webinar is recommended for providers who care for at risk patients and staff involved in the authorization process.

Date:    Feb 4       

Time: 12:15

Location: Online only. Link will be emailed to registrants with reminder one day prior to the event.

*****NO CODING CEUs for this event*******

2026 Physician Fee Schedule:  lunchtime program Feb 4 Presented by: Karen Scott, MEd, RHIA, CCS-P, CPC, FAHIMA

2026 Physician Fee Schedule:  lunchtime program Feb 4

Presented by: Karen Scott, MEd, RHIA, CCS-P, CPC, FAHIMA

Karen will discuss some details from the CMS 2026 Physician Fee Schedule, focusing on fee schedule changes that can directly and indirectly affect billing and coding.

Date:               Wednesday, February 4 and 18, 2026  

Time:               12:15 PM- 1:00 PM.         

Location:        Online only. Link will be emailed to registrant 1 day prior. 1 Hour CEU

     ******* for MetroCare members and staff only****